Last updated: April 8, 2026
What are the primary manufacturers and suppliers of DESMODA?
DESMODA is a branded formulation of desmopressin acetate used primarily for diabetes insipidus, bedwetting, and bleeding disorders such as von Willebrand disease and hemophilia A. The drug is available in various formulations, including nasal spray, tablets, and injections.
Key Manufacturing Companies and Their Market Status
| Company Name |
Country of Origin |
Formulations |
Market Share |
Approval Status |
Notes |
| Ferring Pharmaceuticals |
Switzerland |
Nasal spray, tablets |
Approx. 60% |
Approved globally (FDA, EMA) |
Leader in desmopressin market. Introduced nasal spray in 1990s. |
| Bachem AG |
Switzerland |
Bulk active pharmaceutical ingredient (API) |
N/A |
Approved in various markets |
Supplies desmopressin API. Sells API for formulation by other manufacturers. |
| Teva Pharmaceutical Industries |
Israel |
Tablets, nasal spray |
Approx. 20% |
Approved in multiple regions |
Focuses on generics. Offers desmopressin products in various markets. |
| Sun Pharmaceutical Industries |
India |
Tablets |
Smaller market share |
Approved in select markets |
Produces generic versions of desmopressin. |
| Akrikhin (part of Siberian Pharmaceuticals) |
Russia |
Injectable formulations |
Niche markets |
Limited approvals |
Focus on regional markets and hospital supply. |
API Suppliers for Desmopressin
Large-scale API suppliers include:
- Bachem AG: Supplies bulk desmopressin API to multiple pharmaceutical firms.
- SMS Pharmaceuticals: India-based producer of peptidic APIs, including desmopressin.
- Fresenius Kabi: Supplies API for hospital injectables, including desmopressin.
Regulatory and Market Considerations
- FDA Approvals: Ferring and Teva have multiple approvals across the U.S., with Ferring being the primary supplier of branded desmopressin.
- EMA Approvals: Both Ferring and Teva hold EMA approvals for European markets.
- Regional Presence: Suppliers like Akrikhin focus on Russia and neighboring countries, primarily providing injectables and regional generics.
Supply Chain Risks and Opportunities
- Concentration of API Production: Dominated by Ferring (API supply and formulation), with limited diversification. Disruption could impact pricing and availability.
- Generic Competition: Increasing entries from Teva and Sun Pharmaceutical create pricing pressure.
- Regional Suppliers: Regional firms (e.g., Akrikhin) provide localized supply but have limited reach.
Summary
The global desmopressin supply chain is primarily controlled by Ferring Pharmaceuticals, with significant API production from Bachem. Generics from Teva and Sun Pharmaceutical increase market competition. Regional players like Akrikhin serve niche markets, mainly in Russia.
Key Takeaways
- Ferring remains the dominant supplier for branded desmopressin and holds most regulatory approvals.
- API is mainly supplied by Bachem and SMS Pharmaceuticals.
- Generics from Teva and Sun Pharma are expanding market presence.
- Supply chains face risks from API concentration and regional dependencies.
- Regulatory approval status varies by region, impacting market access for different suppliers.
FAQs
Q1: Who is the leading manufacturer of DESMODA?
A1: Ferring Pharmaceuticals is the leading manufacturer of desmopressin-based products, including DESMODA.
Q2: Which companies supply desmopressin API?
A2: Bachem AG and SMS Pharmaceuticals are primary API suppliers.
Q3: Are there generic versions of DESMODA?
A3: Yes, companies like Teva and Sun Pharmaceutical produce generic desmopressin formulations.
Q4: In which markets is DESMODA approved?
A4: Desmopressin is approved in North America, Europe, Asia, and various other regions, depending on regulatory filings.
Q5: What are the supply chain risks for desmopressin?
A5: Risks include API supply concentration, regional manufacturing dependencies, and regulatory approval variability.
References
[1] European Medicines Agency. (2022). Desmopressin summary. EMA.
[2] U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalents. FDA.
[3] Bachem AG. (2022). API Product Portfolio. Bachem.
[4] Teva Pharmaceutical Industries. (2022). Product approvals and market filings. Teva.
[5] Sun Pharmaceutical Industries. (2022). Product information and approvals. Sun Pharma.
